• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23488 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Andalusian Health Technology Assessment Area (AETSA) [Laser interstitial thermal therapy for patients with refractory epilepsy: safety and effectiveness. A systematic review]
1995     Basque Office for Health Technology Assessment (OSTEBA) [Laser excimer in ophthalmology]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Laser angioplasty of coronary arteries]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Laronidase (Aldurazyme) for the treatment of mucopolysaccharidosis I]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Lapatinib or trastuzumab in combination with aromatase Inhibitors for hormone receptor positive/ErbB2-positive breast cancer]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Lapatinib (Tyverb) for the treatment of metastatic breast cancer]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Laparoscopy versus laparotomy in treatment of early stage endometrial cancer: a multi-centre cost-effectiveness study]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic vertical sleeve gastrectomy vs. laparoscopic Roux-en Y gastric bypass for the treatment of obesity]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic versus conventional surgery in colorectal cancer]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic surgery in kidney neoplasms]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery in colorectal cancer : quality of life, psychological impact and patient satisfaction]
2009     Norwegian Knowledge Centre for the Health Services (NOKC) [Laparoscopic surgery for benign gynaecological disease]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery effectiveness and safety vs open surgery in colorectal cancer]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic peritoneal lavage for patients with perforated diverticulitis]
2013     The Netherlands Organisation for Health Research and Development (ZonMw) [Laparoscopic ileocolic resection versus infliximab treatment of recurrent distal ileitis in Crohn's disease: a randomized multicenter trial]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic hysterectomy and lymphadenectomy efficacy and safety in endometrial cancer]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Laparoscopic and endoscopic cooperative surgery for gastrointestinal tumor]
2009     Committee for New Health Technology Assessment (CNHTA) [Laparoscopic adjustable gastric banding for morbid obesity]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Laparoscopic (non robotic) radical prostatectomy versus open radical prostatectomy in localized prostate cancer]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Laminar air flow in the operating room to prevent hip and knee arthroplasty infections]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Lacosamide in epilepsy]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Labour care in healthy women.Study of variability and systematic review]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [L-methionine in patients with neurogenic bladder disorders]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Kyphoplasty and vertebroplasty for the treatment of osteoporotic vertebral compression fractures- observational study]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures - 1st Update 2010]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [Korean guidelines for the prophylactic use of white blood growth factors]
2006     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Knee arthrosis patient management in primary care clinical practice guideline (CPG)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Kinanthropometric nutritional assessment]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Ki-67 proliferative index in patients with early breast cancer]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Key items for developing and implementing a high complexity/cost surgical implants registry for its postmarketing surveillance]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Key factors in Electronic Clinical Guides: Breast Cancer]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet in drug-resistant epilepsy]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet in central nervous system tumors]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet for refractory epilepsy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketoanalogue diet for advanced chronic kidney failure]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketoanalogs in association with high protein diet in chronic kidney failure]
2023     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Judicious use of 14 laboratory tests]
2009     Committee for New Health Technology Assessment (CNHTA) [JAK2 gene exon 12 mutation analysis]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis in children and adolescents) - Addendum to Commission A20-65]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (axial spondyloarthritis) - Addendum to Commission A20-66]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (cholangiocarcinoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivosidenib (acute myeloid leukaemia, IDH1 R132 mutation, first line, combination with azacitidine) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Ivermectin for COVID-19]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [homozygous for the F508del mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [heterozygous for F508del and MF mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, RF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, other/unknown mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Benefit assessment according to §35a Social Code Book]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, gating mutation, heterozygous) – Benefit assessment according to §35a]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, RF mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, other/unknown mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, MF mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, MF mutation, heterozygous) - Addendum to Project A23-122]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 2 to 5 years, F508del mutation, homozygous) – Addendum to Project A23-123]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis) - Addendum to Commissions G20-18, G20-20, A20-77, A20-83]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, from 12 to < 24 months, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 to < 12 months, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 6 months to < 18 years, with R117H mutation)- Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 4 to < 6 months, with R117H mutation) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 4 to < 6 months, gating mutation) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 2 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 18 years and older, with R117H mutation) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 12 years and older, diverse mutations) - Benefit assessment according to §35a Social Code Book]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with tezacaftor/ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with tezacaftor/ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with tezacaftor/ivacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Addendum to Commission A19-71]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, gating mutation, heterozygous) - Benefit assessment according to §35a Social Code Book]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, residual function mutation) - Benefit assessment according to §35a Social Code Book]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Addendum to Commission A20-83]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Addendum to Commission A20-77]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Addendum to Commission A19-70]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]